Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Saved in:
| Title: | Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. |
|---|---|
| Authors: | Park YH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. yhparkhmo@skku.edu.; Department of Health Science and Technology, School of Medicine & SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. yhparkhmo@skku.edu., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea. moisa@snu.ac.kr., Park K; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea., Wen J; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Lee KH; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Choi YL; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Department of Health Science and Technology, School of Medicine & SAIHST, Sungkyunkwan University, Seoul, Republic of Korea., Lee WC; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Min A; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Bonato V; Biostatistics, Pfizer Inc, San Diego, CA, USA., Park S; Department of Health Science and Technology, School of Medicine & SAIHST, Sungkyunkwan University, Seoul, Republic of Korea., Ram S; Drug Safety R&D, Pfizer Inc, San Diego, CA, USA., Lee DW; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Kim JY; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Lee SK; Research Center for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea., Lee WW; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Lee J; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Kim M; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Kim HS; Pfizer Oncology, Seoul, Republic of Korea., Weinrich SL; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Ryu HS; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Kim TY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Dann S; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Kim YJ; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Fernandez DR; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Koh J; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Wang S; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Park SY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Deng S; Biostatistics, Pfizer Inc, San Diego, CA, USA., Powell E; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Ravi RK; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Bienkowska J; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Rejto PA; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA., Park WY; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Department of Health Science and Technology, School of Medicine & SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea., Kan Z; Oncology Research & Development, Pfizer Inc, San Diego, CA, USA. zhengyan.kan@pfizer.com. |
| Source: | Genome medicine [Genome Med] 2023 Jul 20; Vol. 15 (1), pp. 55. Date of Electronic Publication: 2023 Jul 20. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101475844 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-994X (Electronic) Linking ISSN: 1756994X NLM ISO Abbreviation: Genome Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
